Find News

Filter articles

Applied Filters

Showing 1 to 10 of 212 results

English High Court upholds Sequenom patent for prenatal test


US-based gene sequencing company Sequenom was handed a win yesterday after a UK court ruled that The Doctors Laboratory and Ariosa Diagnostics, which is owned by Roche, had infringed its patent.

US patent reforms could re-establish gene patent eligibility, industry experts warn


A group of more than 100 medical, scientific, patient advocacy and women’s health organisations have opposed a recent proposal to amend section 101 of the US Patent Act.

Danish biotech company secures CRISPR licence

Denmark, Ireland04-06-2019

Danish research company Bioneer has secured a non-exclusive licence to CRISPR/Cas9 technology owned by French geneticist Emmanuelle Charpentier.

Sensorion in gene therapy collaboration with Institut Pasteur


Biopharmaceutical company Sensorion has entered into a research collaboration with French research body Institut Pasteur.

BGI takes Illumina to court over patent infringement in US

Denmark, Germany, US29-05-2019

A subsidiary of China-based genome sequencing company BGI has filed a patent infringement suit against a US competitor.

University of California granted fifth CRISPR patent


The US Patent and Trademark Office has issued a new CRISPR/Cas9 patent to the University of California, the University of Vienna and microbiologist Emmanuelle Charpentier.

Google fund invests in CRISPR start-up


Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.

Charpentier granted new CRISPR/Cas9 patent


ERS Genomics has announced a new CRISPR/Cas9 US patent for use of the gene-editing technology in a single guide format.

US university treats cancer patients with CRISPR


The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.

Catalent to buy $1.2bn gene therapy company


Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.

Showing 1 to 10 of 212 results